Form 4: Athira Pharma CFO Granted Stock Options

Athira Pharma's Chief Financial Officer, Robert Renninger, was granted options to purchase 34,358 shares of common stock with an exercise price of $4.07.

Summary

• Robert Renninger, Chief Financial Officer of Athira Pharma, Inc. (ATHA), was granted an option to purchase 34,358 shares of common stock.
• The stock option has an exercise price of $4.07 per share, which was the closing price on the Nasdaq Global Market on the grant date.
• The option was granted on September 24, 2025, and reported with a transaction date of December 24, 2025.
• Vesting of the option is contingent upon satisfying both a milestone requirement and a service-based requirement.
• The milestone requirement was satisfied on December 23, 2025.
• The service-based requirement dictates that 50% of the shares will vest on December 23, 2026, with the remaining 50% vesting at a rate of 1/36th per month thereafter, subject to continued employment.
• The option is scheduled to expire on September 23, 2035.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a key executive, which is generally a positive for aligning management incentives with shareholder interests. It reflects standard compensation practices and the achievement of a company milestone, without indicating any negative operational or financial news.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The satisfaction of a milestone requirement on December 23, 2025, indicates progress on a specific company objective.

Risks

• The vesting of the stock options is subject to a service-based requirement, meaning the CFO must remain employed by Athira Pharma through the vesting dates to realize the full benefit.
• The value of the options is dependent on the future market price of Athira Pharma's common stock exceeding the exercise price of $4.07; if the stock price falls below this, the options may be worthless.

Future Outlook

The vesting schedule of the stock options ties the Chief Financial Officer's long-term compensation directly to the company's future performance and his continued service, aligning executive incentives with shareholder value creation over several years.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This form of equity compensation aligns the interests of management with those of shareholders by linking personal wealth creation to the company's stock performance and long-term strategic goals.

Comparison to Industry Standards

• Equity incentive plans, including stock option grants with performance and service-based vesting conditions, are standard compensation tools for executives in publicly traded companies, particularly within the biotech sector.
• The structure of this grant, with both milestone and time-based vesting, is consistent with common practices designed to reward both specific achievements and sustained contributions.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Renninger, the Chief Financial Officer, constitutes a related party transaction as it involves compensation between the company and an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from aligned management incentives for long-term value creation.
• Employees: No direct impact on general employees mentioned, but the CFO's continued service is incentivized.

Next Steps

• Robert Renninger's continued service as Chief Financial Officer will be required for the service-based portion of the stock options to vest.
• The company will continue to work towards increasing shareholder value to make the options profitable for the executive.

Key Dates

Keywords

Athira Pharma, ATHA, Robert Renninger, CFO, Stock Option, Equity Incentive, SEC Form 4, Insider Transaction, Vesting, Common Stock, Executive Compensation